Sign up to save your podcasts
Or
Share Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Jennifer Wargo, MD, MMSc - Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The panelists will tackle topics such as the use of checkpoint inhibitors as standard adjuvant therapy in stage III/IV melanoma; the potential of adjuvant immunotherapy in stage II disease; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging novel immune-based treatments in resectable melanoma (eg, LAG-3 inhibitors). This program will help inform the identification of optimal candidates for immunotherapy, address treatment selection and dosing considerations, and support effective management of immune-related events. Upon completion of this CE activity, participants will be able to: Summarize updated evidence and guideline recommendations supporting the use of adjuvant and neoadjuvant immunotherapy in resectable or potentially resectable melanoma, including in stage II, III, and IV settings, Select appropriate adjuvant immunotherapy options for patients with resected melanoma requiring additional treatment, including those with BRAF-mutant and wild-type disease, Integrate neoadjuvant immunotherapy into the management of patients with melanoma who may benefit from presurgical treatment, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/WUW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the practice-changing evidence supporting the use of immunotherapy in resectable melanoma? In this activity, a panel of surgical and medical oncology experts will guide you through these new developments and provide insights on the real-world use of immunotherapy in resectable melanoma, including expanded applications of immunotherapy. The panelists will tackle topics such as the use of checkpoint inhibitors as standard adjuvant therapy in stage III/IV melanoma; the potential of adjuvant immunotherapy in stage II disease; efficacy, safety, and dosing information on neoadjuvant immunotherapy; and emerging novel immune-based treatments in resectable melanoma (eg, LAG-3 inhibitors). This program will help inform the identification of optimal candidates for immunotherapy, address treatment selection and dosing considerations, and support effective management of immune-related events. Upon completion of this CE activity, participants will be able to: Summarize updated evidence and guideline recommendations supporting the use of adjuvant and neoadjuvant immunotherapy in resectable or potentially resectable melanoma, including in stage II, III, and IV settings, Select appropriate adjuvant immunotherapy options for patients with resected melanoma requiring additional treatment, including those with BRAF-mutant and wild-type disease, Integrate neoadjuvant immunotherapy into the management of patients with melanoma who may benefit from presurgical treatment, Manage immune-related adverse events in patients with melanoma receiving immunotherapy in conjunction with surgery.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
318 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
114 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
485 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Oncology Today with Dr Neil Love
54 Listeners
CCO Oncology Podcast
9 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners